Publications

1. Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri CJ, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo RD, Nadeem O, Mann H, Kalariya N, Hovanky V, DeAvila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr MM, Htut M, McGuirk JP, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. Blood. 2024 Oct 4 Epub 2024 Oct 04
   View PubMed
2. Koehler AB, Rabe KG, Crusan DJ, Call TG, Achenbach SJ, Hampel PJ, Kenderian SS, Leis JF, Wang Y, Muchtar E, Tsang M, Hilal T, Parrondo R, Bailey KR, Ding W, Bailen R, Schwager SM, Shi M, Hanson CA, Slager SL, Kay NE, Ashrani AA, Parikh SA. Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism. J Thromb Haemost. 2024 Sep 27 Epub 2024 Sept 27
   View PubMed
3. Rees MJ, Mammadzadeh A, Bolarinwa A, Elhaj ME, Bohra A, Bansal R, Ailawadhi S, Parrondo R, Chhabra S, Khot A, Hayman S, Dispenzieri A, Buadi F, Dingli D, Warsame R, Kapoor P, Gertz MA, Muchtar E, Kourelis T, Gonsalves W, Rajkumar SV, Lin Y, Kumar S. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024 Jul 23; 14 (1):122 Epub 2024 July 23
   View PubMed
4. Zanwar S, Le-Rademacher J, Durot E, D'Sa S, Abeykoon JP, Mondello P, Kumar S, Sarosiek S, Paludo J, Chhabra S, Cook JM, Parrondo R, Dispenzieri A, Gonsalves WI, Muchtar E, Ailawadhi S, Kyle RA, Rajkumar SV, Delmer A, Fonseca R, Gertz MA, Treon SP, Ansell SM, Castillo JJ, Kapoor P. Simplified Risk Stratification Model for Patients With Waldenstrom Macroglobulinemia. J Clin Oncol. 2024 Jul 20; 42 (21):2527-2536 Epub 2024 May 24
   View PubMed
5. Ailawadhi S, Adu Y, Frank RD, Das S, Hodge DO, Fernandez A, Flott C, Elliott J, Parrondo R, Sher T, Roy V, Chanan-Khan AA. Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities. Blood Cancer J. 2024 May 28; 14 (1):86
   View PubMed
6. Parrondo RD, Dutta N, LaPlant BR, Elliott J, Fernandez A, Zimmerman A, Cicco G, Han B, Heslop K, Chapin D, Sher T, Roy V, Rasheed A, Das S, Chanan-Khan AA, Paulus A, Ailawadhi S. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2024 May; 204 (5):1825-1829 Epub 2024 Jan 29
   View PubMed
7. Parrondo RD, Ailawadhi S, Cerchione C. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives. Front Oncol. 2024; 14:1394048 Epub 2024 Apr 10
   View PubMed
8. Alhaj Moustafa M, Parrondo R, Abdulazeez MF, Roy V, Sher T, Alegria VR, Warsame RM, Fonseca R, Rasheed A, Gonsalves WI, Kourelis T, Kapoor P, Buadi FK, Dingli D, Hayman SR, Reeder CB, Chanan-Khan AA, Ailawadhi S. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma. Anticancer Drugs. 2024 Jan 1; 35 (1):63-69 Epub 2023 Apr 06
   View PubMed
9. Yadav U, Kumar SK, Baughn LB, Dispenzieri A, Greipp P, Ketterling R, Jevremovic D, Buadi FK, Dingli D, Lacy MQ, Fonseca R, Bergsagel PL, Ailawadhi S, Roy V, Parrondo R, Sher T, Hayman SR, Kapoor P, Leung N, Cook J, Binder M, Muchtar E, Warsame R, Kourelis TV, Go RS, Lin Y, Seth A, Lester SC, Breen WG, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. Blood. 2023 Nov 30; 142 (22):1871-1878
   View PubMed
10. Das S, Ailawadhi S, Sher T, Roy V, Fernandez A, Parrondo RD. Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety. Curr Oncol. 2023 Oct 31; 30 (11):9627-9633
    View PubMed
11. Yassine F, Kharfan-Dabaja MA, Tsalantsanis A, Roy V, Zubair AC, Murthy HS, Ayala E, Iqbal M, Sher T, Ailawadhi S, Parrondo RD. Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience. Bone Marrow Transplant. 2023 Oct; 58 (10):1130-1136 Epub 2023 July 21
    View PubMed
12. Ailawadhi S, Ailawadhi M, Dutta N, Parrondo RD, Roy V, Sher T, Baksh M, Rasheed A, Das S, Fernandez AJ, Paulus A, Chanan-Khan AA. The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers. Cancer Med. 2023 Sep; 12 (18):19013-19020 Epub 2023 Aug 17
    View PubMed
13. Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. 2023 Jul 15; 129 (14):2179-2191 Epub 2023 Apr 06
    View PubMed
14. Ailawadhi S, Chen Z, Huang B, Paulus A, Collins MC, Fu LT, Li M, Ahmad M, Men L, Wang H, Davids MS, Liang E, Mekala DJ, He Z, Lasica M, Yannakou CK, Parrondo R, Glass L, Yang D, Chanan-Khan A, Zhai Y. Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial. Clin Cancer Res. 2023 Jul 5; 29 (13):2385-2393
    View PubMed
15. Ailawadhi S, Parrondo RD, Dutta N, Han B, Ciccio G, Cherukuri Y, Alegria VR, LaPlant BR, Roy V, Sher T, Edwards B, Lanier S, Manna A, Heslop K, Caulfield T, Maldosevic E, Storz P, Manochakian R, Asmann Y, Chanan-Khan AA, Paulus A. AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma. Cancers (Basel). 2023 Jan 12; 15 (2)
    View PubMed
16. Parrondo RD, Iqbal M, Von Roemeling R, Von Roemeling C, Tun HW. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies. Front Immunol. 2023; 14:1239082 Epub 2023 Oct 26
    View PubMed
17. Mohty R, Alotaibi S, Gadd M, Luo Y, Parrondo R, Qin H, Kharfan-Dabaja MA. Chimeric Antigen Receptor T-cell Therapy for Chronic Lymphocytic Leukemia: What is the supporting evidence so far? Clin Hematol Int. 2023; 5 (4):33-46 Epub 2023 Nov 28
    View PubMed
18. Ailawadhi S, Parrondo RD, Moustafa MA, LaPlant BR, Alegria V, Chapin D, Roy V, Sher T, Paulus A, Chanan-Khan AA. Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results. Hematol Oncol. 2022 Oct; 40 (4):695-703 Epub 2022 May 08
    View PubMed
19. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Kenderian SS, Muchtar E, Wang Y, Koehler AB, Parrondo R, Schwager SM, Shi M, Braggio E, Slager SL, Kay NE, Parikh SA. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. Br J Haematol. 2022 Oct; 199 (2):239-244 Epub 2022 July 16
    View PubMed
20. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Chanan-Khan AA, Kenderian SS, Muchtar E, Wang Y, Ailawadhi S, Koehler AB, Parrondo R, Schwager SM, Sher T, Hanson CA, Shi M, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. Blood Cancer J. 2022 Sep 1; 12 (9):124 Epub 2022 Sept 01
    View PubMed
21. Parrondo RD, Paulus A, Ailawadhi S. Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma. Cancers (Basel). 2022 Jul 8; 14 (14) Epub 2022 July 08
    View PubMed
22. Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD Jr, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplant Cell Ther. 2022 Feb; 28 (2):83.e1-83.e9 Epub 2021 Nov 12
    View PubMed
23. Abdel Rahman ZH, Parrondo RD, Heckman MG, Wieczorek M, Miller KC, Alkhateeb H, Sproat LZ, Murthy H, Hogan WJ, Kharfan-Dabaja MA, Peterson JF, Baughn LB, Hoppman N, Litzow MR, Ketterling RP, Greipp PT, Foran JM. Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia. Br J Haematol. 2022 Feb; 196 (4):963-968 Epub 2021 Oct 25
    View PubMed
24. Baksh M, Li K, Jiang L, Alegria V, Sher T, Roy V, Chanan-Khan A, Ailawadhi S, Parrondo RD, Alhaj Moustafa M. Myelomatous ascites and pleural effusion in relapsed multiple myeloma. Clin Case Rep. 2022 Feb; 10 (2):e05329 Epub 2022 Feb 02
    View PubMed
25. Pasvolsky O, Yeshurun M, Fraser R, Estrada-Merly N, Rozovski U, Shargian-Alon L, Assal A, Banerjee R, Bumma N, Gale RP, Hagen P, Holmberg L, Hossain NM, Lazarus HM, Lee C, Mian H, Miller KC, Nathan S, Nagler A, Nishihori T, Parrondo RD, Patel S, Schroeder MA, Usmani SZ, Wang T, Wirk B, Kumar S, Shah N, Qazilbash MH, D'Souza A. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplant. 2022 Jan; 57 (1):31-37 Epub 2021 Oct 04
    View PubMed
26. Kase AM, Bullock C, Parrondo R, Alhaj Moustafa M, Iqbal M, Li KD, Parent EE, Tun H. Neuropsychiatric Manifestations of Lymphoma-Associated Cerebral Glucose Hypometabolism Can Be Reversed by Intensive Glucose Supplementation. Blood Lymphat Cancer. 2022; 12:17-21 Epub 2022 Mar 23
    View PubMed
27. Baksh M, Jiang L, Bhatia U, Alegria V, Sher T, Roy V, Chanan-Khan A, Ailawadhi S, Parrondo RD. Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature. Clin Case Rep. 2021 Dec; 9 (12):e05181 Epub 2021 Dec 07
    View PubMed
28. Jayakrishnan T, Aulakh S, Baksh M, Nguyen K, Ailawadhi M, Samreen A, Parrondo R, Sher T, Roy V, Manochakian R, Paulus A, Chanan-Khan A, Ailawadhi S. Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting. Cancers (Basel). 2021 Nov 18; 13(22).
    View PubMed
29. Parrondo RD, Moustafa MA, Reeder C, Sher T, Roy V, Muchtar E, Warsame R, Alegria V, Gonsalves W, Dingli D, Hayman S, Kapoor P, Chanan-Khan AA, Ailawadhi S. Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2021 May; 21 (5):355-360 Epub 2021 Jan 12
    View PubMed
30. Parrondo RD, Reljic T, Iqbal M, Ayala E, Kharfan-Dabaja MA, Kumar A, Murthy HS. Efficacy of proteasome inhibitor-based maintenance following autologous transplantation in multiple myeloma: A systematic review and meta-analysis. Eur J Haematol. 2021 Jan; 106 (1):40-48 Epub 2020 Oct 16
    View PubMed
31. Parrondo RD, Majeed U, Sher T. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis. Br J Haematol. 2020 Dec; 191 (5):673-681 Epub 2020 May 01
    View PubMed
32. Parrondo RD, Reljic T, Iqbal M, Ayala E, Tun HW, Kharfan-Dabaja MA, Kumar A, Murthy HS. Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenstrom Macroglobulinemia: A Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2020 Oct; 20 (10):e694-e711 Epub 2020 June 02
    View PubMed
33. Melody M, Parrondo R, Alhaj Moustafa M, Wu K, Menke D, Seim L, Tun HW. Follicular lymphoma associated paraneoplastic myositis. Clin Case Rep. 2020 Oct; 8 (10):2003-2006 Epub 2020 July 23
    View PubMed
34. Chumsri S, Sokol ES, Soyano-Muller AE, Parrondo RD, Reynolds GA, Nassar A, Thompson EA. Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature. J Natl Compr Canc Netw. 2020 May; 18 (5):517-521
    View PubMed
35. Fernandez Turizo MJ, Kharfan-Dabaja MA, Alhaj Moustafa M, Ayala E, Jiang L, Parrondo R. Primary diffuse large B-cell lymphoma presenting as acute appendicitis: A report of 2 cases and a literature review. Clin Case Rep. 2020 Feb; 8 (2):293-298 Epub 2020 Jan 07
    View PubMed
36. Parrondo RD, Ailawadhi S, Sher T, Chanan-Khan AA, Roy V. Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies. JCO Oncol Pract. 2020 Feb; 16 (2):56-66
    View PubMed
37. Parrondo RD, Roy V, Sher T, Alegria V, Chanan-Khan AA, Ailawadhi S. Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review. Case Rep Hematol. 2020; 2020:4360926 Epub 2020 Feb 18
    View PubMed
38. Parrondo RD, Sher T. Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma. Onco Targets Ther. 2019; 12:8467-8478 Epub 2019 Oct 14
    View PubMed
39. Sanchez L, Sylvester M, Parrondo R, Mariotti V, Eloy JA, Chang VT. In-Hospital Mortality and Post-Transplantation Complications in Elderly Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Population-Based Study. Biol Blood Marrow Transplant. 2017 Jul; 23 (7):1203-1207 Epub 2017 Mar 09
    View PubMed
40. Rios C, D'Ippolito G, Curtis KM, Delcroix GJ, Gomez LA, El Hokayem J, Rieger M, Parrondo R, de Las Pozas A, Perez-Stable C, Howard GA, Schiller PC. Low Oxygen Modulates Multiple Signaling Pathways, Increasing Self-Renewal, While Decreasing Differentiation, Senescence, and Apoptosis in Stromal MIAMI Cells. Stem Cells Dev. 2016 Jun 1; 25 (11):848-60 Epub 2016 May 09
    View PubMed
41. Reiner T, de Las Pozas A, Parrondo R, Palenzuela D, Cayuso W, Rai P, Perez-Stable C. Mcl-1 protects prostate cancer cells from cell death mediated by chemotherapy-induced DNA damage. Oncoscience. 2015; 2 (8):703-15 Epub 2015 Sept 01
    View PubMed
42. Nguewa P, Manrique I, Diaz R, Redrado M, Parrondo R, Perez-Stable C, Calvo A. Id-1B, an alternatively spliced isoform of the inhibitor of differentiation-1, impairs cancer cell malignancy through inhibition of proliferation and angiogenesis. Curr Mol Med. 2014 Jan; 14 (1):151-62
    View PubMed
43. Parrondo R, de Las Pozas A, Reiner T, Perez-Stable C. ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells. PeerJ. 2013; 1:e144 Epub 2013 Sept 12
    View PubMed
44. Reiner T, Parrondo R, de Las Pozas A, Palenzuela D, Perez-Stable C. Betulinic acid selectively increases protein degradation and enhances prostate cancer-specific apoptosis: possible role for inhibition of deubiquitinase activity. PLoS One. 2013; 8 (2):e56234 Epub 2013 Feb 12
    View PubMed
45. Parrondo R, de las Pozas A, Reiner T, Rai P, Perez-Stable C. NF-kappaB activation enhances cell death by antimitotic drugs in human prostate cancer cells. Mol Cancer. 2010 Jul 9; 9:182 Epub 2010 July 09
    View PubMed
46. Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, Catena R, Collantes M, Penuelas I, Diaz-Gonzalez JA, Calvo A. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer. 2010 May 11; 10:188
    View PubMed
47. Reiner T, de Las Pozas A, Parrondo R, Perez-Stable C. Progression of prostate cancer from a subset of p63-positive basal epithelial cells in FG/Tag transgenic mice. Mol Cancer Res. 2007 Nov; 5 (11):1171-9 Epub 2007 Nov 02
    View PubMed